RCFB60c7, RCi177
UCLi004-B
General
Cell Line |
|
hPSCreg name | UCLi004-B |
Cite as: | UCLi004-B (RRID:CVCL_EE26) |
Alternative name(s) |
RCFB60c7, RCi177
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
UCLi004-C (RCi172, RCFB60c2) Donor's gene variants: C9orf72, C9orf72 Donor diseases: Amyotrophic lateral sclerosis Frontotemporal dementia UCLi004-A (RCi173, RCFB60c6) Donor's gene variants: C9orf72, C9orf72 Donor diseases: Amyotrophic lateral sclerosis Frontotemporal dementia UCLi002-A (HHItC9D-V34, DN19) Donor's gene variants: C9orf72, C9orf72 Donor diseases: Frontotemporal dementia LUBi001-B (PGRN-8310, RCFB58 c4.4, PGRN8310, RCi194) Donor's gene variants: GRN, GRN, GRN, GRN Donor diseases: Frontotemporal dementia LUBi001-C (PGRN-8310, RCFB58 c3.7, RCi200, PGRN8310) Donor's gene variants: GRN, GRN, GRN, GRN Donor diseases: Frontotemporal dementia PFIZi013-A (RCi215, RCFB59 C9) Donor's gene variants: TARDBP, TARDBP Donor diseases: Amyotrophic lateral sclerosis |
Last update | 28th April 2022 |
User feedback | |
Provider |
|
Generator | University College London (UCL) |
Distributors | |
External Databases |
|
BioSamples | SAMEA4084285 |
Cellosaurus | CVCL_EE26 |
Wikidata | Q54989671 |
General Information |
|
Projects | |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
|
Donor Information
General Donor Information |
|
Sex | male |
Age of donor (at collection) | 50-54 |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
Genetic variants
The donor was not diagnosed with FTD at the time of sample collection. FTD is listed due to the association with C9ORF72.
Synonyms
Genetic variants
C9ORF72 hexanucleotide repeat expansion
|
Donor Relations |
|
Other cell lines of this donor | |
External Databases (Donor) |
|
BioSamples | SAMEA3964276 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | No |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | Yes |
Please provide the contact information | Selina Wray |
Is there other documentation provided to the donor for consenting purposes? | Yes |
Confirm that consent was obtained by a qualified professional | Yes |
Has the donor agreed to be re-contacted? | No |
Has the donor been informed about how her/his data will be protected? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Does consent pertain to a specific research project? | No |
Does consent permit unforeseen future research, without further consent? | Yes |
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
Does consent expressly prevent development of commercial products? | No |
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
an academic institution? | Yes |
a public organisation? | Yes |
a non-profit company? | Yes |
a for-profit corporation? | Yes |
Does consent expressly permit collection of genetic information? | Yes |
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
How may genetic information associated with the cell line be accessed? | Open Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
Does consent permit access to medical records of the donor? | No |
Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Institute of Neurology Joint Research Ethics Committee |
Approval number | 09/H0716/64 |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | Institute of Neurology Joint Research Ethics Committee |
Approval number | 09/H0716/64 |
Do you have obligations to third parties in regard to the use of the cell line? | No |
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.; These cells may be vimentin-positive, fibronectin-positive, fsp1-positive, MMP-1-positive, collagen I-positive, collagen III-positive, and alpha-SMA-negative.
|
Age of donor (at collection) | 50-54 |
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Sendai virus |
Genes | |
Vector free reprogramming |
|
Type of used vector free reprogramming factor(s) |
None
|
Other |
|
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzyme-free cell dissociation
EDTA
|
O2 Concentration | 20 % |
CO2 Concentration | 5 % |
Medium |
Essential 8™
|
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
POU5F1 (OCT-4) |
Yes |
|
||||
SSEA-4 |
Yes |
|
||||
TRA 1-60 |
Yes |
|
||||
SSEA-1 |
No |
|
Differentiation Potency
In vitro spontaneous differentiation
Marker | Expressed |
PAX6 |
Yes |
HES5 |
Yes |
NEUROD1 |
Yes |
Microbiology / Virus Screening |
|
HIV 1 | Negative |
HIV 2 | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Certificate of Analysis |
|
Is there a certificate of analysis available? |
Yes
Passage:
18
|
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
46,XY
Passage number: 19
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.